Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome
New assay bringsvalidated HRD technology from Myriad Geneticsto the Illumina TruSight Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression SAN DIEGO, June 23, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test, codeveloped with Merck (known as MSD outside the United States and Canada). The research test builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research c...
Source: singaporestar.com